News
2d
Everyday Health on MSNZepbound Beats Wegovy for Weight Loss in First Head-to-Head TrialIn a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
19hon MSN
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
5d
The Manila Times on MSNZepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugsPeople taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in ...
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
A trial was conducted comparing weight loss medications Zepbound and Wegovy. Results from the trial found that participants ...
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results